Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.40 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16799709 | 1.00 | LMNA (0.42) | LMNAITGB3ITGA2BSMN1; SMN2SIGMAR1 | |
| SCHEMBL20810530 | 0.92 | LMNA (0.41) | LMNAITGB3ITGA2BSMN1; SMN2SIGMAR1 | |
| SCHEMBL16799902 | 0.90 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2SIGMAR1TMEM97KMT2A | |
| SCHEMBL16799903 | 0.90 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2SIGMAR1TMEM97KMT2A | |
| SCHEMBL17977261 | 0.90 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2SIGMAR1TMEM97KMT2A | |
| SCHEMBL16800065 | 0.89 | SMN1; SMN2 (0.40) | LMNASMN1; SMN2SIGMAR1TMEM97KMT2A | |
| SCHEMBL16800064 | 0.89 | SMN1; SMN2 (0.40) | LMNASMN1; SMN2SIGMAR1TMEM97KMT2A | |
| SCHEMBL16800066 | 0.89 | SMN1; SMN2 (0.40) | LMNASMN1; SMN2SIGMAR1TMEM97KMT2A | |
| SCHEMBL2763234 | 0.89 | SMN1; SMN2 (0.40) | LMNASMN1; SMN2SIGMAR1TMEM97KMT2A | |
| SCHEMBL2763233 | 0.89 | SMN1; SMN2 (0.40) | LMNASMN1; SMN2SIGMAR1TMEM97KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077369-B1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2019-03-13 | — | — | EP | disclosed |
| EP-3077369-B1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9908843-B2 | Benzamide derivatives useful in the treatment of muscular disorders and pain and for controlling spasticity and tremors | CANBEX THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-9908843-B2 | Benzamide derivatives useful in the treatment of muscular disorders and pain and for controlling spasticity and tremors | CANBEX THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-9908843-B2 | Benzamide derivatives useful in the treatment of muscular disorders and pain and for controlling spasticity and tremors | CANBEX THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| EP-3256112-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | Canbex Therapeutics Limited (GB) | 2017-12-20 | — | — | EP | disclosed |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2016-10-20 | — | — | US | disclosed |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2016-10-20 | — | — | US | disclosed |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2016-10-20 | — | — | US | disclosed |
| EP-3077369-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERSAND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | Canbex Therapeutics Limited (GB) | 2016-10-12 | — | — | EP | disclosed |
| WO-2016128771-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128771-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| WO-2015082938-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERSAND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | CANBEX THERAPEUTICS LIMITED (GB) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015082938-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERSAND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | CANBEX THERAPEUTICS LIMITED (GB) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | HCN4, KCNJ4, KCNQ4 | LMNA 2664/4885ITGB3 3271/4885ITGA2B 4010/4885 |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | MUSK, MYLK2, CBR3 | LMNA 2797/4885ITGB3 1652/4885ITGA2B 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.